Diffuse central neuronal involvement in Fabry disease: A proton MRS imaging study

Neurology

Volumn 52, Issue 8, 1999, Pages 1663-1667

  Tedeschi, Gioacchino ^a,b   Bonavita, S ^a   Banerjee, T K ^a   Virta, A ^a   Schiffmann, R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; LACTIC ACID; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BASAL GANGLION; BRAIN INFARCTION; CLINICAL ARTICLE; FABRY DISEASE; HUMAN; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER; X CHROMOSOME LINKED DISORDER;

EID: 0033549065     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.8.1663     Document Type: Article

References (28)

1. Desnick RJ, Ioannou YA, Eng CH. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 6th ed. New York: McGraw Hill, 1996:2741-2784.
2. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-1749.
3. Mitsias P, Levine SR. Cerebrovascular complications of Fabry disease. Ann Neurol 1996:40:8-17.
4. Lou HL, Reske-Nielsen E. The central nervous system in Fabry disease: a clinical, pathological and biochemical investigation. Arch Neurol 1971;25:351-359.
5. Rahman AN, Lindenberg R. The neuropathology of hereditary dystrophic lipidosis. Arch Neurol 1963;9:373-385.
6. de Veber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992;31:409-415.
7. 1H NMR markers of neuronal and glial disorders. NMR Biomed 1989;2:196-200.
8. Jackson EF. In vivo magnetic resonance spectroscopy in humans: a brief review. Am J Physiologic Imag 1992;7:146-154.
9. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23-31.
10. 1H NMR spectroscopy: N-acetylaspartate, creatine and choline. NMR Biomed 1991;4:47-52.
11. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131-134.
12. Moffett JR, Namboodiri MA, Neale JH. Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 1993;41:559-570.
13. Prichard JW, Brass LM. New anatomical and functional imaging methods. Ann Neurol 1992;32:395-400.
14. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989.
15. Petroff OA, Graham GB, Blamire AM, et al. Spectroscopic imaging of stroke in humans: histopathological correlates of spectral changes. Neurology 1992;42:1349-1354.
16. Duyn JH, Gillen J, Sobering G, et al. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-282.
17. Tedeschi G, Bertolino A, Righini A, et al. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 1995;45:1384-1391.
18. Barker PB, Gillard JH, van Zijl PCM, et al. Acute stroke: evaluation with serial proton MR spectroscopic imaging. Radiology 1994;192:723-732.
19. Kruse B, Barker PB, van Zijl PC, et al. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994;36:595-608.
20. Tedeschi G, Bertolino A, Lundbom N, et al. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology 1996;47:696-704.
21. Tedeschi G, Bertolino A, Massaquoi SG, et al. Proton magnetic resonance spectroscopic imaging in cerebellar degeneration. Ann Neurol 1996;39:71-78.
22. Tedeschi G, Schiffmann R, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse white matter hypomyelination. Neurology 1995;45:1526-1532.
23. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson disease and corticobasal degeneration. Brain 1997;120:1541-1552.
24. Benner RE, Munro PMG, Williams SCR, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho/Cr ratio. Magn Reson Med 1993;29:737-745.
25. 1H magnetic resonance spectroscopy study. Magn Reson Med 1995;33:595-600.
26. Vion-Dury J, Nicoli F, Salvan AM, et al. Reversal of brain metabolic alterations with zidovudine detected by proton localized magnetic resonance spectroscopy. Lancet 1995;345: 60-61.
27. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1955;34:721-727.
28. Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy: evidence from proton MR spectroscopic imaging. Neurology 1998;49:1525-1533.